A fundamental challenge in HIV vaccine development has been overcome with the demonstration that specialized immune cells can be coaxed into producing broadly protective antibodies against the virus's most vulnerable spots. This breakthrough could reshape vaccine strategies for one of medicine's most elusive targets. Scientists engineered a precision-designed HIV vaccine component called Q23-APEX-GT2 that successfully activated rare B cells responsible for producing broadly neutralizing antibodies in rhesus macaques. These antibodies target the V2-apex region of HIV's outer shell, a critical vulnerability that allows the virus to attach to host cells. The engineered immunogen consistently triggered focused immune responses across genetically diverse macaques, generating multiple lineages of antibody-producing cells with the long heavy-chain structures characteristic of potent HIV-fighting antibodies. Isolated antibodies from vaccinated macaques demonstrated broad recognition of different HIV variants and showed measurable cross-neutralization against diverse tier-2 viruses, representing strains that typically resist standard antibody responses. Structural analysis confirmed that the antibodies bound precisely to their intended targets using mechanisms nearly identical to the most effective human broadly neutralizing antibodies discovered to date. This represents the first successful induction of authentic broadly neutralizing antibody precursors in outbred primates, moving beyond previous limitations seen only in laboratory mice. The achievement validates germline-targeting as a viable vaccine strategy and suggests that training the immune system to recognize HIV's conserved vulnerabilities may finally be feasible. While significant optimization remains before human trials, this proof-of-principle establishes that engineering vaccines to activate specific antibody-producing cells can generate the cross-protective responses essential for HIV prevention.